FIG 3.
(A) Ribavirin accumulation in mock and HEK293-hCNT1 cells compared with accumulation in mock cells. *, P < 0.05. (B) FTC accumulation in mock and HEK293-hCNT1 cells in the absence or presence of phlorizin (CNT inhibitor). ***, P < 0.001 versus mock cells; ###, P < 0.001 versus no inhibitor. (C) Concentration-dependent profiles of FTC uptake in HEK293-hCNT1. (D) HEK293-hCNT1-mediated uptake was analyzed by means of the Eadie-Hofstee plot. (E) Entecavir accumulation in mock and MDCK-hCNT3 cells in the absence or presence of phlorizin (CNT inhibitor) and FTC. ***, P < 0.001 versus mock cells; ###, P < 0.001 versus no inhibitor. (F) FTC accumulation in mock and MDCK-hCNT3 cells.